Bölümler
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Verdiva has entered the competitive obesity market with a $410 million debut, focusing on next-generation therapies. The company's lead asset is an oral glp-1 receptor agonist that can be dosed weekly, aiming to improve accessibility and affordability. In 2024, the biopharma industry saw a significant increase in first-time VC funding, totaling $7.7 billion over 137 deals. J.P. Morgan predicts a strong year for biopharma in 2025, with an uptick in M&A activity and FDA decisions to watch. The FDA has proposed setting a bar for weight-loss therapies as the obesity space heats up. Lilly has won Medicare coverage for Zepbound in sleep apnea, while Vanda criticizes the FDA's conduct after a drug rejection. Layoffs have affected the gene therapy space, with companies like Resilience and Scribe cutting staff. Overall, the outlook for biopharma in 2025 is cautiously optimistic, with opportunities for innovation and growth.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Galapagos is set to split into two entities by mid-2025, creating a new innovative medicines specialist and a cell therapy company. Novo has invested $4.6 billion to expand its deal with Valo, aiming to maintain leadership in the cardiometabolic space. Tenvie, supported by venture partners, will be focusing on developing brain-penetrant small molecules for neurological and metabolic diseases.The trend of licensing deals in the pharmaceutical industry is on the rise, with experts debating whether it is a sign of desperation or a crucial part of the biotech ecosystem. Roche is in the final stages of acquiring Poseida for up to $1.5 billion, while Cassava has had to lay off a third of its staff following a setback in an Alzheimer's drug trial. Major pharmaceutical companies are looking towards China for potential deal opportunities, despite regulatory uncertainty in the region. The FDA is considering setting a bar for weight-loss therapies as the obesity space continues to heat up. Looking ahead to 2025, there is a cautiously optimistic outlook for the biopharma industry, with predictions of increased M&A activity leading up to key events like the J.P. Morgan Healthcare Conference and important FDA decisions.As licensing deals become more common in the biotech industry, big pharma companies are exploring partnerships in China. The industry is gearing up for the J.P. Morgan Healthcare Conference with a sense of uncertainty after M&A activity did not meet expectations in 2024. Biospace's NextGen Class of 2025 features startups focusing on emerging trends in biopharma, attracting investments from major players.Companies like Roche, Merck, and Novo are making significant moves in the biopharma space, shaping the industry landscape. Job opportunities are available in various sectors, including positions like Chief of Staff and Senior Director in IT and Translational Neuroscience. Biospace is working on enhancing user experience by personalizing emails based on individual preferences.Thank you for tuning in to Pharma and Biotech Daily, where we bring you the latest updates and insights from the world of pharmaceuticals and biotechnology.
-
Eksik bölüm mü var?
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a promising development in the fight against the global pandemic.## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received FDA emergency use authorization for its COVID-19 vaccine. This is another step forward in the efforts to combat the spread of the virus.## Johnson & Johnson vaccine shows promising results in early trialsJohnson & Johnson's COVID-19 vaccine has shown promising results in early trials, with a single-dose option being tested. This could potentially streamline the vaccination process.## AstraZeneca faces setbacks in COVID-19 vaccine productionAstraZeneca has faced setbacks in the production of its COVID-19 vaccine, leading to delays in distribution. This highlights the challenges of scaling up production to meet global demand.## Novartis announces acquisition of The Medicines CompanyNovartis has announced the acquisition of The Medicines Company in a deal worth over $9 billion. This strategic move will expand Novartis' portfolio in the cardiovascular space.## Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease, which aims to detect the disease at an earlier stage. This could lead to improved outcomes for patients.## Gilead Sciences receives FDA approval for new HIV treatmentGilead Sciences has received FDA approval for a new HIV treatment, expanding options for patients living with the virus. This demonstrates ongoing innovation in the field of infectious diseases.## Merck announces positive results for cancer immunotherapy drugMerck has announced positive results for its cancer immunotherapy drug, showing promising efficacy in treating certain types of cancer. This represents a significant advancement in oncology research.## Sanofi partners with Translate Bio on mRNA vaccinesSanofi has partnered with Translate Bio to develop mRNA vaccines for infectious diseases, including COVID-19. This collaboration leverages cutting-edge technology to address global health challenges.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has acquired a Wuxi Biologics facility in Ireland for $500 million, expanding manufacturing operations in the biopharma industry. Analysts predict Viking Therapeutics as a top candidate amid higher M&A activity. Danish biotech Orbis has secured $93 million in funding for developing oral medicines. Evidence is growing on the benefits of GLP-1s in treating heart disease beyond weight loss and blood sugar control. Lilly has opened a new facility to drive innovation in bringing medicines to market, while Novo has filed a citizen petition to block compounded Victoza. Roche has invested $1 billion for another ADC from China. Various job opportunities are available in the industry, with insights on Alzheimer's treatment, Novo vs. Lilly's performance, and updates on FDA decisions and lawsuits related to GLP-1 products.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly has requested to join a lawsuit against the FDA filed by compounding pharmacies, indicating the outcome could impact its business. Despite having inferior GLP-1 products, Novo Nordisk is outperforming Lilly due to superior marketing strategies. The pharmaceutical industry is seeing an increase in hiring for computational biology and data science roles. Regeneron's acquisition of Oxular has resulted in the elimination of the Oxular workforce.In other news, Roche has committed potential funding for an ADC from China, Neumora's depression drug failed in pivotal trials, and Sangamo's stock dropped as Pfizer ended a gene therapy pact. Job opportunities include positions in marketing, experimental medicine, external engagement, and congress meeting planning.
-
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world.Roche has recently finalized a new deal in China valued at up to $1 billion for an antibody-drug conjugate. However, Neumora's depression drug trial has unfortunately not yielded successful results. Additionally, Sangamo has experienced a setback by losing a partnership with Pfizer in hemophilia gene therapy. On a more positive note, Axsome has released mixed data from Alzheimer's trials but still plans to move forward with filing for FDA approval.In other recent developments, Merck's PAH drug and BMS' Opdivo injection have received regulatory greenlights. It's important to note that there are currently job opportunities available in various pharmaceutical companies for those looking to make a career move in the industry.Looking ahead to 2024, the neurobiopharma industry has been characterized as a rollercoaster of ups and downs.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##News 1: Pfizer announces positive results from COVID-19 vaccine trialPfizer has announced positive results from its phase 3 trial of a COVID-19 vaccine. The vaccine was found to be over 90% effective in preventing the virus. This is a significant milestone in the fight against the pandemic.##News 2: Moderna's COVID-19 vaccine shows promising resultsModerna has also reported promising results from its COVID-19 vaccine trial. The vaccine was found to be over 94% effective in preventing the virus. This is another positive development in the race to find a safe and effective vaccine.##News 3: Novartis receives FDA approval for new cancer treatmentNovartis has received FDA approval for a new cancer treatment. The treatment is a targeted therapy that has shown promising results in clinical trials. This approval provides new hope for patients with certain types of cancer.##News 4: Roche launches new diagnostic test for Alzheimer's diseaseRoche has launched a new diagnostic test for Alzheimer's disease. The test is designed to detect biomarkers associated with the disease, allowing for earlier diagnosis and treatment. This could have a significant impact on patient outcomes.##News 5: Johnson & Johnson announces breakthrough in HIV vaccine researchJohnson & Johnson has announced a breakthrough in HIV vaccine research. The company has developed a mosaic-based vaccine that has shown promising results in early-stage clinical trials. This could be a major step forward in the fight against HIV.##News 6: AstraZeneca partners with Oxford University on COVID-19 treatmentAstraZeneca has partnered with Oxford University on a potential COVID-19 treatment. The treatment is an antibody cocktail that has shown positive results in early trials. This collaboration could help accelerate the development of much-needed treatments for the virus.##Thank you for listening to Pharma and Biotech Daily. Stay tuned for more updates on the latest news and developments in the industry.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.##FDA Approves New Drug for Alzheimer's DiseaseThe FDA has recently approved a new drug for the treatment of Alzheimer's disease. This drug has shown promising results in clinical trials, with patients experiencing a significant improvement in cognitive function. This is a major breakthrough in the treatment of Alzheimer's, as there have been few advancements in this area in recent years. The approval of this new drug is expected to have a significant impact on the lives of those suffering from this devastating disease.##Major Pharmaceutical Company Announces MergerA major pharmaceutical company has announced plans to merge with another leading company in the industry. This merger is expected to create a powerhouse in the pharmaceutical world, with combined resources and expertise that will drive innovation and growth. The new company is set to become a major player in the global pharmaceutical market, with a strong presence in key therapeutic areas. This merger is a significant development in the industry and is expected to have a major impact on the competitive landscape.##Breakthrough in Cancer Treatment ResearchResearchers have made a significant breakthrough in the field of cancer treatment. A new therapy has been developed that has shown promising results in clinical trials, with patients experiencing a significant reduction in tumor size and improved survival rates. This breakthrough has the potential to revolutionize the way cancer is treated, offering new hope to patients around the world. The research team behind this therapy is now working towards gaining FDA approval, with hopes of bringing this groundbreaking treatment to market in the near future.##Global Vaccine Distribution EffortsEfforts are underway to distribute COVID-19 vaccines to countries around the world, with a focus on ensuring equitable access for all populations. Global organizations and governments are working together to overcome logistical challenges and ensure that vaccines reach those who need them most. This global vaccine distribution effort is crucial in the fight against the pandemic, and will play a key role in achieving herd immunity and bringing an end to the crisis. The success of these distribution efforts will depend on collaboration and coordination at an international level, with the goal of reaching as many people as possible in a timely manner.##New Drug Shows Promise in Treating Rare DiseaseA new drug has shown promise in treating a rare genetic disease that affects a small number of patients worldwide. Clinical trials have demonstrated that this drug can effectively target the underlying cause of the disease, leading to improvements in symptoms and quality of life for patients. This breakthrough offers hope to those suffering from rare diseases, providing a potential treatment option where none existed before. The research team behind this drug is now working towards gaining regulatory approval, with plans to make it available to patients in the near future.##Innovations in Gene TherapyAdvancements in gene therapy are opening up new possibilities for treating a wide range of genetic disorders. Researchers are developing innovative gene editing techniques that can target specific genes and correct mutations that cause disease. These advancements have the potential to revolutionize the treatment of genetic disorders, offering hope to patients who previously had limited options for treatment. The field of gene therapy is rapidly evolving, with new breakthroughs being made on a regular basis. The future looks bright for gene therapy, with the potential to transform the lives of patients around the world.##That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest developments in the pharmaceutical and biotechnology industries.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Pfizer announces positive results for COVID-19 vaccinePfizer has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 90%. This is a significant development in the fight against the pandemic, as it could potentially lead to widespread vaccination and a return to normalcy. ## Moderna receives FDA emergency use authorization for COVID-19 vaccineModerna has received emergency use authorization from the FDA for its COVID-19 vaccine. This is another important step in the fight against the pandemic, as it will allow for the vaccine to be distributed more widely and help to protect more people from the virus. ## Johnson & Johnson applies for emergency use authorization for COVID-19 vaccineJohnson & Johnson has applied for emergency use authorization from the FDA for its COVID-19 vaccine. If approved, this vaccine could provide another option for individuals looking to protect themselves from the virus. ## AstraZeneca faces scrutiny over COVID-19 vaccine dataAstraZeneca is facing scrutiny over the data from its COVID-19 vaccine trials. Questions have been raised about the efficacy of the vaccine, as well as potential safety concerns. This is a reminder of the importance of transparency and thorough evaluation in the development of vaccines. ## Novavax announces positive results for COVID-19 vaccineNovavax has announced positive results for its COVID-19 vaccine, with an efficacy rate of over 85%. This is another promising development in the fight against the pandemic, as it could provide yet another option for vaccination. ## ConclusionIn conclusion, there have been several significant developments in the world of COVID-19 vaccines. From positive results to emergency use authorizations, these updates are a testament to the hard work and dedication of researchers and scientists around the world. As we continue to navigate this challenging time, it is important to stay informed and vigilant in our efforts to combat the pandemic.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ##News 1: Pfizer announces positive results for new cancer drugPfizer has recently announced positive results from a phase 3 clinical trial for their new cancer drug. The drug showed a significant increase in overall survival rates compared to standard treatments. This is great news for patients with this type of cancer and could potentially lead to a new treatment option in the near future.##News 2: FDA approves new gene therapy for rare genetic disorderThe FDA has approved a new gene therapy for a rare genetic disorder that affects children. This therapy has shown promising results in clinical trials, with patients experiencing significant improvements in their symptoms. This approval marks a major milestone in the field of gene therapy and provides hope for patients with rare genetic disorders.##News 3: Biogen announces breakthrough Alzheimer's drugBiogen has announced a breakthrough in the treatment of Alzheimer's disease with their new drug. The drug has shown to significantly slow the progression of the disease in clinical trials, offering hope to millions of patients and their families. This development could potentially change the landscape of Alzheimer's treatment moving forward.##News 4: Moderna ramps up production of COVID-19 vaccineModerna has announced plans to ramp up production of their COVID-19 vaccine in order to meet global demand. The company has already distributed millions of doses worldwide, with plans to increase production even further in the coming months. This is a positive step towards achieving widespread vaccination and controlling the spread of the virus.##News 5: Novartis partners with research institute on new drug discoveryNovartis has entered into a partnership with a leading research institute to collaborate on new drug discovery efforts. This collaboration brings together expertise from both organizations to accelerate the development of innovative therapies for patients. The partnership highlights the importance of collaboration in driving scientific advancements in the pharmaceutical industry.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.## Pfizer announces positive results for COVID-19 vaccinePfizer has recently announced positive results from their phase 3 clinical trial for their COVID-19 vaccine. The vaccine showed over 90% effectiveness in preventing COVID-19 in participants. This is a promising development in the fight against the pandemic.## Moderna seeking emergency use authorization for COVID-19 vaccineModerna is seeking emergency use authorization from the FDA for their COVID-19 vaccine. The vaccine has shown promising results in clinical trials and could be available to the public soon. This is another step forward in the race to develop a safe and effective vaccine against COVID-19. ## AstraZeneca facing challenges with COVID-19 vaccine trialAstraZeneca has faced challenges with their COVID-19 vaccine trial, as some participants experienced adverse reactions. The company has paused the trial to investigate these reactions and ensure the safety of the vaccine. This highlights the importance of rigorous testing and monitoring in vaccine development.## Johnson & Johnson pauses COVID-19 vaccine trialJohnson & Johnson has also paused their COVID-19 vaccine trial due to an unexplained illness in a participant. The company is investigating the illness to determine if it is related to the vaccine. This pause emphasizes the need for thorough safety monitoring in clinical trials.## Roche launches rapid antigen test for COVID-19Roche has launched a rapid antigen test for COVID-19 that provides results in just 15 minutes. The test is designed for use in point-of-care settings and can help quickly identify individuals infected with the virus. This could be a valuable tool in controlling the spread of COVID-19.## Novartis acquires Vedere BioNovartis has acquired Vedere Bio, a company focused on developing gene therapies for vision loss. This acquisition expands Novartis' capabilities in gene therapy and strengthens their position in the ophthalmology market. It also demonstrates Novartis' commitment to advancing innovative treatments for patients with vision disorders.## Gilead Sciences receives FDA approval for TrodelvyGilead Sciences has received FDA approval for Trodelvy, a treatment for metastatic triple-negative breast cancer. Trodelvy has shown promising results in clinical trials and provides a new treatment option for patients with this aggressive form of breast cancer. This approval represents an important milestone in the fight against breast cancer.## Vertex Pharmaceuticals acquires Semma TherapeuticsVertex Pharmaceuticals has acquired Semma Therapeutics, a company focused on developing cell-based therapies for diabetes. This acquisition enhances Vertex's pipeline in regenerative medicine and strengthens their commitment to finding a cure for diabetes. It also highlights the growing interest in cell therapy as a treatment approach for chronic diseases.## Eli Lilly announces positive results for Alzheimer's drugEli Lilly has announced positive results from their phase 2 clinical trial for an Alzheimer's drug targeting amyloid plaques in the brain. The drug showed a significant reduction in amyloid levels compared to placebo, indicating potential disease-modifying effects. This is a hopeful development in the search for effective treatments for Alzheimer's disease.## Amgen launches biosimilar of AvastinAmgen has launched a biosimilar of Avastin, a widely used cancer drug that targets blood vessel growth in tumors. The biosimilar, known as Mvasi, offers a more affordable alternative to Avastin while maintaining similar efficacy and safety profiles. This provides patients with greater access to critical cancer treatments at lower costs.## ConclusionIn conclusion, there have been several significant developments in the Pharma and Biotech industry recently. From promising results for COVID-19 vacci
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## New Drug Approval: The FDA has approved a new drug for the treatment of a rare genetic disorder. This drug has shown promising results in clinical trials and is expected to provide hope for patients suffering from this condition.## Acquisition News: A major pharmaceutical company has announced the acquisition of a smaller biotech firm. This strategic move is aimed at strengthening the company's pipeline and expanding its portfolio of products.## Clinical Trial Results: Results from a phase III clinical trial have shown positive outcomes for a new cancer treatment. This breakthrough therapy has the potential to significantly improve survival rates for patients with this type of cancer.## Regulatory Update: The FDA has issued a warning letter to a pharmaceutical company for failing to comply with regulatory requirements. This action highlights the importance of maintaining high standards of safety and efficacy in the development and approval of new drugs.## Research Advancement: Researchers have discovered a novel mechanism of action for a promising drug candidate. This groundbreaking finding could lead to the development of more effective treatments for a variety of diseases.## Market Analysis: Analysts predict strong growth in the biotech sector over the next few years. This bullish outlook is driven by increasing investment in research and development, as well as growing demand for innovative therapies.Stay tuned for more updates on the latest developments in the Pharma and Biotech industry. Thank you for listening.
-
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in Pharma and Biotech world.In 2024, the biopharma industry experienced both successes and setbacks in the field of neuroscience drug development. Companies like Bristol Myers Squibb, Eli Lilly, and AbbVie saw highs and lows throughout the year. Despite a still-tight business environment, there were some breakthroughs in the industry. Layoffs continued to be a trend, with companies like Bayer, Bristol Myers Squibb, and Johnson & Johnson cutting hundreds or thousands of employees. Clinical trial flops were also prevalent, especially in the neuro space where success rates are particularly low. Mergers and acquisitions remained relatively small in 2024, with Novo Holdings' acquisition of Catalent being the largest deal at $16.5 billion. The year also saw significant advancements in areas such as immuno-oncology, obesity clinical programs, and next-generation oncology drug classes. Additionally, there were legal challenges and regulatory developments that impacted the industry. The FDA approved landmark drugs and therapies throughout the year, including Lilly's GLP-1 for sleep apnea. Job opportunities in the biopharma industry continued to be available across various roles and companies.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.In 2025, VC funds are expected to follow the data when investing in biopharma companies, as high profile failures and long timeframes for revenue have shifted investment away from phase I. To attract VC dollars, companies must bring solid data to the table, according to Pitchbook's 2025 outlook. Additionally, GLP-1 receptor agonists, known for their use in diabetes and obesity treatments, have now expanded into the cardiovascular and sleep apnea markets. They also show potential in other indications such as cancer, addiction, and neurodegenerative diseases. Applied Therapeutics has faced challenges with a significant drop in share price due to FDA rejection and a warning letter. On a positive note, Lilly's Zepbound has received approval as the first-ever sleep apnea drug for adults with obesity. Other companies such as Vertex have also received FDA approval for new treatment options. Novo's recent blunder highlights the high investor expectations for weight loss drugs. Overall, the biopharma industry is constantly evolving with new approvals and advancements in various therapeutic areas.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk's weight loss drug, cagrisema, failed to meet investor expectations of achieving 25% weight loss, causing the stock to plummet. Galectin's stock also tumbled after its lead asset missed the primary endpoint in a phase IIb/III trial. On a positive note, Ionis' Tryngolza became the first FDA-approved therapy for familial chylomicronemia syndrome. GSK posted mixed survival data for the Jemperli/Zejula combo in first-line ovarian cancer treatment. Intelligencia AI accurately predicted high-potential biotechs before the ASH conference, showcasing the reliability of its AI-driven methodology. Overall, the biopharma industry is seeing a mix of successes and setbacks in various drug developments and approvals.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Vertex Pharmaceuticals experienced a 13% decrease in its share price following the disappointing results of its non-opioid pain therapy, suzetrigine, in a Phase II trial. Meanwhile, major players like Bayer, Bristol Myers Squibb, and Johnson & Johnson announced significant layoffs, impacting hundreds or even thousands of employees. Roche also faced setbacks as their Parkinson's drug failed to meet expectations in a mid-stage trial. Novartis made the decision to cut jobs in both Boston and Munich, while Mesoblast celebrated FDA approval for a mesenchymal stromal cell therapy for GVHD.On a more positive note, the FDA confirmed that there is no shortage of Lilly's GLP-1s and provided compounding pharmacies with a grace period before implementing new regulations to halt their production. Intelligencia AI's accurate pre-ASH predictions for high-potential biotechs demonstrated the efficacy of its predictive AI methodology. Amidst these challenges and changes, the biopharma industry is navigating evolving market dynamics and making strategic decisions to adapt to the shifting landscape.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Merck has entered the obesity pill race with a $2 billion deal with Hansoh, allowing them to compete in the crowded oral GLP-1 space. The FDA issued warning letters against GLP-1 compounders, and the EMA will investigate the eye risk for Novo Nordisk's Ozempic. Novo has also collaborated with Photys to add a novel approach to their cardiometabolic pipeline. Intelligencia AI accurately predicted high-potential biotechs before the ASH conference, showcasing the reliability of its predictive AI methodology. Tenaya stock crashed due to underwhelming data on cardio gene therapy, with a focus on scaling in 2024. Manufacturing has become the hottest target in biopharma, with all of pharma vying for capacity and talent. AbbVie's Humira held 105 patents, preventing biosimilar competition for over 20 years, prompting discussions on policy reforms to prevent unjust extensions of drug monopolies. Moderna investors are advised to hold after a steep drop in 2024. The year saw cautious IPOs, restraint, and breakthroughs. BMS' cost-cutting campaign is in progress, while AbbVie continues its deal-making spree. Lilly and Pfizer executives express an optimistic outlook. Layoffs occurred at Outlook Therapeutics. Novo Holdings successfully closed its $16.5 billion acquisition of Catalent, despite facing pressure from various stakeholders to block the deal. The acquisition was approved by both the European Commission and the Federal Trade Commission, raising concerns about competition in the CDMO sector.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Moderna faced a challenging year with declining share values, prompting analysts to recommend holding onto their stock. Meanwhile, Merck experienced setbacks in its cancer drug pipeline, leading to the termination of two candidates following disappointing late-stage results.In other news, J&J's FDA bid for subcutaneous Rybrevant was rejected due to manufacturing facility issues. On the other hand, Regeneron and Bayer are looking to expand into retinal vein occlusion with their drug Eylea amidst biosimilar competition.Intelligencia AI made headlines after successfully predicting high-potential biotechs before a conference, showcasing the reliability of its predictive methodology. Additionally, there have been FDA approvals in atopic dermatitis, layoffs at Outlook Therapeutics, and recent job postings in the biotech industry.
-
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Danish regulators have raised concerns about a rare eye disease associated with Novo Nordisk's GLP-1 drug, Ozempic, prompting a request for a formal EU review. The FTC has approved Novo Holdings' acquisition of Catalent, allowing the deal to proceed. Bristol Myers Squibb is aiming to reduce costs by $1.5 billion by 2025, while PepGen is facing an FDA hold on its Duchenne muscular dystrophy treatment trial. Intelligencia AI's accurate pre-ASH predictions for biotechs demonstrate the reliability of their AI methodology.In other news, there are advancements in molecular glue degraders, AbbVie continues its deal-making spree, Novo Nordisk reaffirms its commitment to a rare disease production facility, and there are ongoing challenges with drugs targeting the amyloid hypothesis. Layoffs at Editas and FDA approvals for Neurocrine and Checkpoint are also making headlines.
-
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Private equity firms Blackstone and Bain Capital are close to finalizing a potential $3 billion deal for Mitsubishi's pharma unit, Mitsubishi Tanabe Pharma. In other news, five drugs have been flagged for unjustified price hikes in 2023 by the Institute for Clinical and Economic Review. Incyte and Iteos are cutting drug candidates from their cancer pipelines due to disappointing data, while the FDA advisory committee has called for more research on Moderna's RSV vaccine after safety issues arose. Layoffs have been announced at Intercept and Editas, and there has been a slowdown in M&A activity in the pharma industry this year. US Pharmacopeia is looking for expert volunteers to work on medicine quality challenges.
- Daha fazla göster
